Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
This entry refers to an uncharacterized long non-coding RNA gene annotated in Ensembl as "novel transcript, antisense to PDE1C." It is expressed antisense to the protein-coding PDE1C locus, but there are no studies linking it to a specific molecular function, disease process, or interaction with drugs. It is not recognized as a therapeutic target in major biomedical resources. Its genomic annotation may serve as a placeholder until experimental data clarify its significance. The transcript is fundamentally different from the well-studied PDE1C protein, which is a dual specificity cyclic nucleotide phosphodiesterase involved in cell signaling and is considered a legitimate therapeutic target in cancers and cardiovascular disease. This lncRNA transcript (ENSG00000300776), by contrast, lacks established molecular function, disease links, or known drug interactions, and is not referenced in clinical, pharmacological, or molecular target databases.
None described
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel transcript, antisense to phosphodiesterase 1C (None established).